Alpha Cognition Inc. Announces Fiscal 2025 Financial Results and Operational Progress Update
Alpha Cognition Inc., a clinical-stage biopharmaceutical company focused on developing innovative treatments for neurodegenerative disorders, has reported its financial results for the fourth quarter and full year ending December 31, 2025, while also providing a comprehensive operational update. The company’s performance over the past year highlights a pivotal transition from development to commercialization, driven largely by the launch and growing adoption of its flagship Alzheimer’s therapy, ZUNVEYL.
Strong Commercial Momentum for ZUNVEYL
Throughout 2025, Alpha Cognition demonstrated significant commercial progress, particularly with ZUNVEYL, which represents the first newly approved oral treatment for Alzheimer’s disease in more than 15 years. The company emphasized that the fourth quarter marked a period of accelerated demand growth, with December emerging as the strongest sales month since the product’s launch.
According to CEO Michael McFadden, increasing repeat prescription orders indicate that ZUNVEYL is moving beyond initial trial usage and becoming integrated into routine care practices, particularly in long-term care settings. This shift is a critical milestone, as sustained utilization and physician confidence are key indicators of long-term commercial success in the Alzheimer’s treatment landscape.
Revenue Growth and Sales Performance
Alpha Cognition reported approximately $2.5 million in net product revenue from ZUNVEYL during the fourth quarter of 2025. Since its launch, the therapy has generated cumulative net product revenues of around $6.8 million by year-end. When combined with $3.4 million in licensing revenue, the company’s total revenue for 2025 reached approximately $10.2 million.
From a volume perspective, the company dispensed 4,941 bottles of ZUNVEYL during the fourth quarter alone, representing a notable 62% increase compared to the previous quarter. December sales stood out, with 1,859 bottles dispensed, underscoring growing physician adoption and patient demand.
Expanding Prescriber Base and Market Penetration
A key driver of this commercial growth has been the steady expansion of Alpha Cognition’s prescriber network. During the fourth quarter, the number of prescribing physicians increased by 50% compared to the prior quarter. Additionally, the number of long-term care facilities prescribing ZUNVEYL grew by 26%, signaling broader acceptance across institutional care environments.
The company’s commercial team also made significant strides in outreach, engaging with 1,986 care homes during the quarter and reaching approximately 4,000 unique facilities since launch. This extensive engagement strategy reflects Alpha Cognition’s focus on building awareness and driving adoption within the long-term care segment, which represents a critical market for Alzheimer’s therapies.
Advancing Payer Coverage and Market Access
Market access remains a central component of Alpha Cognition’s commercialization strategy. During the fourth quarter, the company successfully secured a second national pharmacy benefit manager (PBM) agreement, bringing its total to two of the four major PBMs serving the long-term care market.
This progress is expected to play a crucial role in improving reimbursement dynamics and reducing access barriers for patients. As payer coverage expands, the company anticipates stronger “pull-through” demand in 2026, further supporting revenue growth and broader adoption of ZUNVEYL.
Clinical Development and Data Generation Initiatives
Beyond commercialization, Alpha Cognition continues to invest in clinical and real-world evidence generation to strengthen ZUNVEYL’s value proposition. The company plans to present new clinical data at major upcoming conferences, including the American Association of Geriatric Psychiatrists annual meeting and the Neuroscience Education Institute Spring Congress in the second quarter of 2026.
In parallel, several important studies are underway or planned:
- BEACON Study: An ongoing real-world study evaluating ZUNVEYL’s impact on cognition, behavior, and tolerability in long-term care patients.
- CONVERGE Study: A planned retrospective analysis involving approximately 400 Alzheimer’s patients, focusing on tolerability, dosing patterns, and polypharmacy considerations.
- RESOLVE Study: A Phase 4 clinical trial designed to further assess ZUNVEYL’s effects on behavioral symptoms and tolerability in Alzheimer’s patients. Data from this study may support future regulatory discussions and help inform both physicians and payers.
These initiatives reflect a broader strategy to generate robust real-world and clinical evidence, reinforcing confidence in ZUNVEYL’s safety and efficacy profile.
Pipeline Expansion and Innovation
Looking ahead, Alpha Cognition is also advancing its pipeline with a focus on improving treatment accessibility and patient experience. The company plans to complete preclinical development of a sublingual formulation of ZUNVEYL and initiate clinical studies in 2026.
This alternative formulation is particularly significant for patients with dysphagia or aphagia—conditions that make swallowing difficult—who currently have limited treatment options. If successfully developed and approved, the sublingual version could represent a meaningful innovation in Alzheimer’s care, addressing an unmet need within a vulnerable patient population.
International Expansion Efforts
In addition to its U.S. commercialization efforts, Alpha Cognition is pursuing international growth through strategic partnerships. The company expects two product approvals outside the United States, particularly in Asian markets, through its partner CMS. These anticipated approvals could open new revenue streams and expand the global footprint of ZUNVEYL.
Strengthened Intellectual Property Position
During 2025, Alpha Cognition also enhanced its intellectual property portfolio with the issuance of an additional U.S. patent covering ZUNVEYL dosing regimens. This development provides added protection for the product and supports the company’s long-term commercialization strategy.
Financial Performance Overview
From a financial standpoint, Alpha Cognition’s transition to a commercial-stage company is reflected in its expense structure and overall profitability metrics.
- Research & Development (R&D) expenses decreased to $1.9 million in 2025, compared to $3.9 million in 2024, as the company shifted focus from development to commercialization.
- Selling, General & Administrative (SG&A) expenses rose significantly to $29.1 million, up from $8.0 million in the previous year, driven by investments in sales infrastructure, personnel, and commercial operations.
- Operating Loss for the year was $22.7 million, compared to $12.0 million in 2024.
- Net Loss totaled $20.7 million, an increase from $14.8 million in the prior year, partially offset by favorable changes in the fair value of warrant liabilities.
Cash Position and Financial Outlook
Despite increased operating expenses, Alpha Cognition strengthened its financial position during the year. The company ended 2025 with $66.0 million in cash, up from $48.5 million at the end of 2024. This improvement was largely driven by a successful capital raise in October 2025, which generated $40 million in net proceeds.
Based on its current operating plan, the company expects its cash reserves to provide a runway of approximately two years. This financial stability positions Alpha Cognition to continue investing in commercial expansion, clinical development, and pipeline innovation while working toward its goal of achieving operational profitability by 2027.
As Alpha Cognition enters 2026, the company remains focused on scaling its commercial operations, expanding payer coverage, and deepening engagement with healthcare providers. With growing adoption of ZUNVEYL, a robust clinical development program, and a strengthened financial foundation, the company is well-positioned to build on its momentum in the evolving Alzheimer’s treatment landscape.
The coming year will be critical as Alpha Cognition seeks to translate early commercial success into sustained growth, while continuing to address the significant unmet needs of patients living with Alzheimer’s disease.
About Alpha Cognition Inc.
Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options.
ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI.
Source Link:https://www.businesswire.com/
